Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18394554 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Wernig G, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-20 18394554
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y694-p - STAT5A (human) ▲
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): ‑, STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TG101348 decrease JAK2 V617F expressing cells

T203-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

Y205-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

T183-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

Y185-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

S235-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

S236-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells

Y694-p - STAT5A (mouse) ▲
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): ‑, STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), erythroblast, HEL (erythroid), myeloid-bone marrow
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TG101348 decrease JAK2 V617F expressing cells
JAK2 (human) increase activated V617F in erythroid cells
IL-3, Epo augment treatment-induced increase in erythroid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase erythroid cells
JAK2 (human) no change compared to control activated V617F in myeloid cells
IL-3, Epo increase in myeloid cells
Epo, IL-3 JAK2 (human) augment treatment-induced increase activated V617F in myeloid cells
TG101348 Epo, IL-3 inhibit treatment-induced increase myeloid cells


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.